Post

New research · Ophthalmology
Journal of current ophthalmology · 15h
Cohort studyJournal of current ophthalmology · 2025

Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study.

Saeed Karimi, Sadra Ashrafi, Seyyed Morteza Hosseini Imeni, Zahra Siavashpour
Read paper
OphthalmologyCohort study

Ruthenium-106 brachytherapy achieved tumor regression in all vasoproliferative tumor and hemangioma cases.

Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study.

Saeed Karimi … Zahra Siavashpour
Journal of current ophthalmology · 2025
Purpose

To evaluate the efficacy and safety of brachytherapy in patients with uveal melanoma and retinal vascular tumors.

Methods

Who received Ruthenium-106 (Ru-106) plaque brachytherapy at the Torfeh Medical Center between March 2016 and March 2022 were examined in this retrospective case-series.

n = 80 patients
Results

every eye tumor (vasoproliferative tumor and hemangioma) shrank after this radiation treatment

74.5%
Melanoma
100%
VPT/RCH
More results

Of the 80 patients, 55 had melanoma, 21 had vasoproliferative tumor (vasoproliferative tumor), and 4 had retinal capillary hemangioma (retinal capillary hemangioma).

Significant relationships were found between tumor characteristics, such as thickness and dose rate at the apex, and treatment outcomes.

More results

Complications included radiation retinopathy and cataract formation, with recurrence rates of 16.4% in melanoma and 7.7% in vasoproliferative tumor/retinal capillary hemangioma.

“
Conclusion · 1 of 3

Ru-106 plaque brachytherapy is effective in treating various intraocular tumors, particularly vasoproliferative tumor/retinal capillary hemangioma.

Conclusion · 2 of 3

Tumor thickness significantly influences treatment outcomes, emphasizing the need for tailored approaches in brachytherapy planning. However, small sample sizes for specific tumor types limited the generalization of the outcomes.

Conclusion · 3 of 3

Future research should focus on refining techniques and mitigating complications to improve patient outcomes in ocular oncology.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving